Legal & General Group
SRNE

Legal & General Group’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Legal & General Group’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-355,278
Closed -$315K – 3417
2022
Q4 		$315K Buy
355,278
+25,325
+8% +$33.6K ﹤0.01% 2452
2022
Q3 		$518K Sell
329,953
-16,028
-5% -$36.4K ﹤0.01% 2335
2022
Q2 		$696K Buy
345,981
+77,177
+29% +$133K ﹤0.01% 2268
2022
Q1 		$627K Buy
268,804
+3,143
+1% +$9.8K ﹤0.01% 2336
2021
Q4 		$1.24M Buy
265,661
+24,990
+10% +$155K ﹤0.01% 2189
2021
Q3 		$1.84M Buy
240,671
+173,764
+260% +$1.47M ﹤0.01% 2060
2021
Q2 		$649K Buy
66,907
+6,544
+11% +$52.1K ﹤0.01% 2294
2021
Q1 		$500K Sell
60,363
-1,962
-3% -$20.7K ﹤0.01% 2305
2020
Q4 		$425K Buy
62,325
+7,106
+13% +$57.1K ﹤0.01% 2292
2020
Q3 		$616K Sell
55,219
-2,136
-4% -$19.5K ﹤0.01% 2158
2020
Q2 		$360K Buy
57,355
+36,033
+169% +$138K ﹤0.01% 2239
2020
Q1 		$39K Sell
21,322
-5,083
-19% -$14.6K ﹤0.01% 2685
2019
Q4 		$89K Buy
26,405
+2,916
+12% +$6.95K ﹤0.01% 2631
2019
Q3 		$50K Hold
23,489
– – ﹤0.01% 2737
2019
Q2 		$80K Hold
23,489
– – ﹤0.01% 2605
2019
Q1 		$111K Buy
23,489
+3,670
+19% +$9.63K ﹤0.01% 2459
2018
Q4 		$47K Buy
19,819
+3,437
+21% +$11.2K ﹤0.01% 2722
2018
Q3 		$72K Buy
16,382
+3,414
+26% +$18.9K ﹤0.01% 2609
2018
Q2 		$93K Buy
+12,968
New +$88.2K ﹤0.01% 2521
2017
Q2 		– Sell
-9,032
Closed -$36K – 3401
2017
Q1 		$36K Sell
9,032
-504
-5% -$2.53K ﹤0.01% 2935
2016
Q4 		$48K Buy
9,536
+4,628
+94% +$27.8K ﹤0.01% 2900
2016
Q3 		$37K Sell
4,908
-946
-16% -$6.37K ﹤0.01% 2660
2016
Q2 		$34K Hold
5,854
– – ﹤0.01% 2669
2016
Q1 		$31K Hold
5,854
– – ﹤0.01% 2582
2015
Q4 		$51K Hold
5,854
– – ﹤0.01% 2453
2015
Q3 		$48K Hold
5,854
– – ﹤0.01% 2473
2015
Q2 		$100K Buy
+5,854
New +$75.2K ﹤0.01% 2114

Other funds holding SRNE

PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return
LCM
Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return
STB
S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return
GA
GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return
HFRG
Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return
GBWM
Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Legal & General Group's SRNE Position: Q1 2023 in Review

Legal & General Group sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 355,278 shares — an estimated $315K sold.

Legal & General Group first reported a position in SRNE in Q2 2015 and held it in 27 quarters. The position peaked at $1.84M in Q3 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

  • Legal & General Group reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Legal & General Group sold 355,278 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $315K.
  • Legal & General Group first reported a position in Sorrento Therapeutics, Inc. in Q2 2015 and held it in 27 quarters.
  • Legal & General Group's Sorrento Therapeutics, Inc. position peaked at $1.84M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Legal & General Group's 13F filing for Q1 2023, filed 15 May 2023.